The research evidence, while preclinical, is compelling
In a large outcomes study of 778 patients, about 71% reported a successful result, which was defined as reducing pain to very low levels after at least 10 VAX-D sessions (Gose et al., 1998)
Khosla, S., Farr, J
The therapeutic mechanism may be associated with accelerated granulation tissue formation, reepithelialization, dermal remodeling, and collagen deposition through ERK1/2 signaling pathway
This is to quickly fix the deficiency
Peptide clears from blood BUT cellular processes continue Duration of cellular effects: Why this matters: Don't need continuous high levels in blood Single injection triggers multi-day effects 2-3x weekly dosing sufficient (not daily required) Cellular "memory" of GHK-Cu exposure Cumulative effects with repeated dosing: Each dose builds on previous Collagen accumulation over weeks Tissue remodeling compounds Results improve with consistent use Comparing GHK-Cu to other peptides Half-life comparison table: GHK-Cu positioning: Short half-life like Ipamorelin But longer cellular effects than half-life suggests Middle-ground dosing frequency (not daily, not weekly) Cumulative benefits with consistency See our BPC-157 guide , TB-500 guide , peptide dosing guide , and peptide dosage chart
